PROTAC

Proteolysis-targeting chimera

PROTACs (Proteolysis Targeting Chimeric Molecules) are heterobifunctional nanomolecules that structurally comprised of two functional motifs linked by a linker. One motif is a small molecule ligand for the target protein of interest, while the other recognizes a specific E3 ligase. By recruiting an E3 ligase to a target protein and formation of a ligase:PROTAC:target ternary complex, A PROTAC leads to polyubiquitylation and subsequent degradation of target through ubiquitin-proteasome system (UPS). PROTACs have desirable features such as the ability to target the “undruggable” proteome and overcome the accumulation of the drug targets and will be promising targeted therapeutics for cancers.

Among the hundreds of E3 ligases, VHL (von Hippel-Lindau disease tumor suppressor protein), CRBN (Cereblon), MDM2 (the mouse double minute 2 homologue) and cIAP (cellular inhibitor of apoptosis 1) are reported to target kinases (such as MEK, KRAS, CDK and Bcr/Abl), transcription factors (such as p53, STAT, RAR, ER and AR), and epigenetic readers (BET bromodomain such as BRD family) and are most widely used in the development of PROTACs. There are also some specific types of PROTACs, such as homo-PROTACs and general PROTACs for tagged fusion proteins. Homo-PROTACs intend to dimerize an E3 ligase and then induce its self-degradation, while general PROTACs for tagged fusion proteins can bind to general tags(such as HaloTag and FKBP12) and then induce the degradation of fusion proteins.

PROTAC Inhibitors

(S,R,S)-AHPC-C6-PEG3-C4-Cl (VH032-C6-PEG3-C4-Cl; VHL Ligand-Linker Conjugates 12; ...)

Cat. No.: HY-103605

(S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.



Purity: 95.04%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG2-C4-Cl (VH032-PEG2-C4-Cl; VHL Ligand-Linker Conjugates 7; E3 ligase Ligand-Linker Conjugates 10)

Cat. No.: HY-103607

(S,R,S)-AHPC-PEG2-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker. (S,R,S)-AHPC-PEG2-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.



Purity: 98.79%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

(S,R,S)-AHPC-PEG6-C4-Cl (VH032-PEG6-C4-Cl; VHL Ligand-Linker Conjugates 10; E3 ligase Ligand-Linker Conjugates 9)

Cat. No.: HY-103606

(S,R,S)-AHPC-PEG6-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 6-unit PEG linker. (S,R,S)-AHPC-PEG6-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

Purity: 96.46%
Clinical Data: No Development Reported
Size: 100 mg, 500 mg, 1 g, 2 g

A1874

Cat. No.: HY-114305

A1874 is a nutlin-based and **BRD4-degrading PROTAC** with a DC_{50} of 32 nM (induce BRD4 degradation in cells). Effective in inhibiting many cancer cell lines proliferation.



Purity: 98.38%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

ACBI1

Cat. No.: HY-128359

ACBI1 is a potent **PROTAC** degrader of BAF ATPase subunits **SMARCA2** and **SMARCA4**, also degrades the polybromo-associated BAF (PBAF) complex member **PBRM1**, with DC_{50}s of 6 nM, 11 nM and 32 nM for SMARCA2, SMARCA4 and PBRM1 in MV-4-11 cells, respectively.



Purity: 98.21%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARCC-4

Cat. No.: HY-130492

ARCC-4 is a low-nanomolar **androgen receptor (AR)** degrader based on **PROTAC**, with a DC_{50} of 5nM. ARCC-4 is an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and outperforms enzalutamide.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ARD-266

Cat. No.: HY-133020

ARD-266 is a highly potent and VHL E3 ligase-based **androgen receptor (AR)** PROTAC degrader. ARD-266 effectively induces degradation of **AR** protein in **AR**-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC_{50} values of 0.2-1 nM.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ARV-771

Cat. No.: HY-100972

ARV-771 is a potent **BET** degrader based on PROTAC technology with K_ds of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for **BRD2(1)**, **BRD2(2)**, **BRD3(1)**, **BRD3(2)**, **BRD4(1)**, and **BRD4(2)**, respectively.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

ARV-825

Cat. No.: HY-16954

ARV-825 is a **BRD4** degrader based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with K_ds of 90 and 28 nM, respectively.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

BETd-246

Cat. No.: HY-115568

BETd-246 is a second-generation and **PROTAC**-based **BET bromodomain (BRD)** inhibitor, exhibiting superior selectivity, potency and antitumor activity.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

BETd-260

(ZBC 260)

Cat. No.: HY-101519

BETd-260 (ZBC 260) is a potent **PROTAC BET** degrader, with as low as 30 pM against **BRD4** protein in RS4;11 leukemia cell line. BETd-260 potently suppresses cell viability and robustly induces **apoptosis** in hepatocellular carcinoma (HCC) cells.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

BI-3663

Cat. No.: HY-111546

BI-3663 is a highly selective **PTK2/FAK PROTAC** (DC_{50}=30 nM), with cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC_{50} of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker.



Purity: 98.14%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BRD4 degrader AT1

Cat. No.: HY-111433

BRD4 degrader AT1 is a highly selective **Brd4** degrader based on **PROTAC** technology, with a K_d of 44 nM for $Brd4^{BD2}$ in cells.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

BSJ-03-123

Cat. No.: HY-111556

BSJ-03-123 is a potent and novel **CDK6**-selective small-molecule degrader (PROTAC).



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

BSJ-03-204

Cat. No.: HY-136250

BSJ-03-204 is a potent and selective Palbociclib-based **CDK4/6** dual degrader (**PROTAC**), with IC_{50}s of 26.9 nM and 10.4 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-03-204 does not induce IKZF1/3 degradation and has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

BSJ-04-132

Cat. No.: HY-136252

BSJ-04-132 is a potent and selective Ribociclib-based **CDK4** degrader (**PROTAC**), with IC_{50}s of 50.6 nM and 30 nM for CDK4/D1 and CDK6/D1, respectively. BSJ-04-132 does not induce CDK6 and IKZF1/3 degradation. BSJ-04-132 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

CP-10

Cat. No.: HY-125835

CP-10 is a PROTAC with highly selective, specific, and remarkable **CDK6** degradation (DC_{50}=2.1 nM). It inhibits proliferation of several haematopoietic cancer cells with impressive potency including multiple myeloma, and can still degrades mutated and overexpressed CDK6.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

CP5V

Cat. No.: HY-130257

CP5V is a **PROTAC**, which specifically degrades **Cdc20** by linking Cdc20 to the VHL/VBC complex for ubiquitination followed by proteasomal degradation. CP5V induces mitotic inhibition and suppresses cancer cell proliferation.

Purity: 98.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CRBN-6-5-5-VHL

Cat. No.: HY-136262

CRBN-6-5-5-VHL is a potent and selective **cereblon (CRBN)** degrader with a DC_{50} value of 1.5 nM. CRBN-6-5-5-VHL has almost no effect on the degradation of the neo-substrates IKZF1 and IKZF3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

dBET1

Cat. No.: HY-101838

dBET1 is a potent **BRD4** protein degrader based on **PROTAC** technology with an EC_{50} of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

dBET57

Cat. No.: HY-123844

dBET57 is a potent and selective degrader of **$BRD4_{BD1}$** based on **PROTAC** technology. dBET57 mediates recruitment to the $CRL4^{CRBN}$ E3 ubiquitin ligase, with a **$DC_{50/5h}$** of 500 nM for **$BRD4_{BD1}$**, and is inactive on $BRD4_{BD2}$.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

dBET6

Cat. No.: HY-112588

dBET6 is a highly potent, selective and cell-permeable degrader of **BET** based on **PROTAC**, with an **IC_{50}** of 14 nM, and has antitumor activity.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

dFKBP-1

Cat. No.: HY-103634

dFKBP-1 is a potent and PROTAC-based **FKBP12** degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of **FKBP12**, the Thalidomide based **cereblon** ligand and a linker.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

DT2216

Cat. No.: HY-130604

DT2216 is a potent and selective **BCL-XL** degrader based on **PROTAC** technology. DT2216 causes effective degradation of BCL-XL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

dTRIM24

Cat. No.: HY-111519

dTRIM24 is a selective bifunctional degrader of **TRIM24** based on **PROTAC**.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FKBP12 PROTAC dTAG-13

(dTAG-13)

Cat. No.: HY-114421

FKBP12 PROTAC dTAG-13 (dTAG-13) is a PROTAC-based heterobifunctional degrader. FKBP12 PROTAC dTAG-13 (dTAG-13) is a degrader of **$FKBP12^{F36V}$** with expression of $FKBP12^{F36V}$ in-frame with a protein of interest.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg

FKBP12 PROTAC dTAG-7

(dTAG-7)

Cat. No.: HY-123941

FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of **$FKBP12^{F36V}$** with expression of $FKBP12^{F36V}$ in-frame with a protein of interest.



Purity: >98.0%
Clinical Data:
Size: 5 mg

FKBP12 PROTAC RC32

(RC32)

Cat. No.: HY-130835

FKBP12 PROTAC RC32 (RC32) is a potent **FKBP12** degrader based on **PROTAC** technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an E3 ubiquitin ligase (Pomalidomide; HY-10984).



Purity: 95.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gefitinib-based PROTAC 3

Cat. No.: HY-123921

Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL ligand via a linker, induces **EGFR** degradation with **DC_{50}**s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

GMB-475

Cat. No.: HY-125834

GMB-475 is a degrader of **BCR-ABL1** tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GNE-987

Cat. No.: HY-129937A

GNE-987 is a highly active chimeric **BET** degrader. GNE-987 exhibits picomolar cell **BRD4** degradation activity (DC_{50}=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC_{50}=4.7 and 4.4 nM, respectively).



Purity: 98.90%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Homo-PROTAC cereblon degrader 1

Cat. No.: HY-111594

Homo-PROTAC cereblon degrader 1 (compound 15a) is a highly potent and efficient **cereblon (CRBN)** degrader with only minimal effects on IKZF1 and IKZF3.



Purity: 99.00%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Homo-PROTAC pVHL30 degrader 1

Cat. No.: HY-111593

Homo-PROTAC pVHL30 degrader 1 is a potent **pVHL30** degrader based on **PROTAC**.

Purity: 99.56%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

KB02-JQ1

Cat. No.: HY-129917

KB02-JQ1 is a highly selective and PROTAC-based **BRD4** degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes **BRD4** degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems.



Purity: 98.29%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

KB02-SLF

Cat. No.: HY-129610

KB02-SLF is a PROTAC-based nuclear **FKBP12** degrader (molecular glue). KB02-SLF promotes nuclear **FKBP12** degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MD-224

Cat. No.: HY-114312

MD-224 is a first-in-class and highly potent small-molecule human murine double minute 2 (**MDM2**) degrader based on the proteolysistargeting chimera (PROTAC) concept.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MG-277

Cat. No.: HY-130122

MG-277, a molecular glue degrader, effectively induces degradation of a translation termination factor, **GSPT1**, with a DC_{50} of 1.3 nM.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MS4078

Cat. No.: HY-112155

MS4078 is an anaplastic lymphoma kinase (**ALK**) **PROTAC** (degrader) with a K_d of 19 nM for binding affinity to ALK.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MT-802

Cat. No.: HY-122562

MT-802 is a potent **BTK** degrader based on **PROTAC** technology, with a DC_{50} of 1 nM. MT-802 has potential to treat C481S mutant chronic lymphocytic leukemia (CLL).



Purity: 98.55%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

MZ 1

Cat. No.: HY-107425

MZ 1 is a **PROTAC BRD4** degrader. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. K_ds of 382/120, 119/115, and 307/228 nM for **BRD4 BD1/2**, BRD3 BD1/2, and BRD2 BD1/2, respectively.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

MZP-54

Cat. No.: HY-112376

MZP-54 is a selective degrader of **BRD3/4** based on **PROTAC** technology, with a K_d of 4 nM for Brd4^{BD2}.

Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

MZP-55

Cat. No.: HY-112377

MZP-55 is a selective degrader of **BRD3/4** based on **PROTAC** technology, with a K_d of 8 nM for Brd4^{BD2}.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC AR Degrader-4

Cat. No.: HY-111848

PROTAC AR Degrader-4 comprises a **cIAP1** ligand binding group, a linker and an **androgen receptor** (**AR**) binding group. PROTAC AR Degrader-4 is an **AR** degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (**SNIPER**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC AR Degrader-4 TFA

Cat. No.: HY-111848A

PROTAC AR Degrader-4 comprises a **cIAP1** ligand binding group, a linker and an **androgen receptor** (**AR**) binding group. PROTAC AR Degrader-4 is an **AR** degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (**SNIPER**s).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

PROTAC B-Raf degrader 1

Cat. No.: HY-111758

PROTAC B-Raf degrader 1 (compound 2) is a proteolysis targeting chimera (PROTAC) for the degradation of **B-Raf**. With anti-cancer activity.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PROTAC Bcl2 degrader-1

Cat. No.: HY-125876

PROTAC Bcl2 degrader-1 (Compound C5) is a **PROTAC**, which potently and selectively induces the degradation of **Bcl-2** (IC_{50}, 4.94 μM; DC_{50}, 3.0 μM) and **Mcl-1** (IC_{50}, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitor Nap-1.



Purity: 98.28%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

PROTAC BET Degrader-1

Cat. No.: HY-103633

PROTAC BET Degrader-1 is a potent **BET** degrader based on **PROTAC**, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC BET Degrader-10

Cat. No.: HY-112718

PROTAC BET Degrader-10 is a potent BET protein **BRD4** degrader extracted from patent WO2017007612A1, example 37, with a DC_{50} of 49 nM.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC BET degrader-2

Cat. No.: HY-114228

PROTAC BET degrader-2 is a highly potent degrader of **Bromodomain and Extra-Terminal (BET)** proteins with an IC_{50} value of 9.6 nM in cell growth inhibition in the RS4;11 cells and capable of achieving tumor regression.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC BET degrader-3

Cat. No.: HY-114229

PROTAC BET Degrader-3 is a potent **BET** degrader based on **PROTAC**.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC BRD4 Degrader-5

Cat. No.: HY-133737

PROTAC BRD4 Degrader-5 is a PROTAC-based **BRD4** degrader. PROTAC BRD4 Degrader-5 can potent degrade **BRD4** in HER2 positive and negative breast cancer cell lines.



Purity: 98.06%
Clinical Data: No Development Reported
Size: 10 mg

PROTAC BRD9 Degrader-1

Cat. No.: HY-103632

PROTAC BRD9 Degrader-1 is a lead **PROTAC BRD9** chemical degrader (IC_{50}=13.5 nM), which can be used as a selective probe useful for the study of BAF complex biology.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PROTAC CDK9 Degrader-1

Cat. No.: HY-103628

PROTAC CDK9 Degrader-1 is a selective **CDK9** degrader.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

PROTAC CDK9 degrader-2

Cat. No.: HY-112811

PROTAC CDK9 degrader-2 (compounds 11c) is a potent and selective **CDK9** degrader based on **PROTAC**, with an IC_{50} of 17 μM in MCF-7 cell lines. Natural product Wogonin binds ubiquitin E3 ligase cereblon (CRBN) via a linker to form PROTAC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC CRBN Degrader-1

Cat. No.: HY-128845

PROTAC CRBN Degrader-1 comprises a **cereblon (CRBN)** ligand binding group, a linker and an **von Hippel-Landau (VHL)** binding group. PROTAC CRBN Degrader-1 is an cereblon (CRBN) degrader.

Purity: 99.34%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC ERα Degrader-1

Cat. No.: HY-112098

PROTAC ERα Degrader-1 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC ERα Degrader-1 extracts from patent WO2017201449A1, compound P1. PROTAC ERα Degrader-1 is an **estrogen receptor-alpha** (**ERα**) degrader.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg

PROTAC ERα Degrader-2

Cat. No.: HY-111846

PROTAC ERα Degrader-2 comprises a **cIAP1** ligand binding group, a linker and an **estrogen receptor α** (**ERα**) binding group. PROTAC ERα Degrader-2 is an **ERα** degrader. Maximal ERα degradation at 30 μM concentration in human mammary tumor MCF7 cells.



Purity: 98.02%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

PROTAC FAK degrader 1

Cat. No.: HY-119932

PROTAC FAK degrader 1 is a selective and potent **focal adhesion kinase (Fak)** degrader with an IC_{50} of 6.5 nM, DC_{50} of 3 nM.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC FKBP Degrader-3

Cat. No.: HY-135345

PROTAC FKBP Degrader-3 is a PROTAC that comprises a **FKBP** ligand binding group, a linker and an **VHL** binding group. PROTAC FKBP Degrader-3 is a potent **FKBP** degrader.



Purity: 98.73%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC FLT-3 degrader 1

Cat. No.: HY-114323

PROTAC FLT-3 degrader 1 is a PROTAC **FLT-3 internal tandem duplication (ITD)** degrader with an IC_{50} 0.6 nM. Anti-proliferative activity; apoptosis induction.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC IDO1 Degrader-1

Cat. No.: HY-131911

PROTAC IDO1 Degrader-1 is the first potent **IDO1 (indoleamine 2,3-dioxygenase 1)** degrader that hijacks IDO1 to CRBN E3 ligase to introduce IDO1 into UPS and eventually achieve ubiquitination and degradation (DC_{50}=2.84 μM).

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC K-Ras Degrader-1

Cat. No.: HY-129523

PROTAC K-Ras Degrader-1 (Compound 518) is potent **K-Ras** degrader based **PROTAC**, exhibits ≥70% degradation efficacy in SW1573 cells.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC KRASG12C Degrader-LC-2

Cat. No.: HY-137516

PROTAC KRASG12C Degrader-LC-2 is a potent and first-in-class degrader of endogenous **KRAS G12C** with DC_{50} values between 0.25 and 0.76 μM. PROTAC KRASG12C Degrader-LC-2 is composed of a covalent KRAS G12C inhibitor MRTX849, a VHL ligand and a linker.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Mcl1 degrader-1

Cat. No.: HY-125877

PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC), is a potently and selectively **Mcl-1** inhibitor with an IC_{50} of 0.78 μM.



Purity: 98.13%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

PROTAC MDM2 Degrader-1

Cat. No.: HY-128840

PROTAC MDM2 Degrader-1 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-1 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-2

Cat. No.: HY-128841

PROTAC MDM2 Degrader-2 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-2 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.



Purity: 98.50%
Clinical Data: No Development Reported
Size: 10 mg, 25 mg

PROTAC MDM2 Degrader-3

Cat. No.: HY-128842

PROTAC MDM2 Degrader-3 is a **MDM2** degrader based on **PROTAC** technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase.

Purity: 98.69%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC RAR Degrader-1

Cat. No.: HY-111844

PROTAC RAR Degrader-1 comprises a **cIAP1** ligand binding group, a linker and a **RAR** ligand binding group. PROTAC RAR Degrader-1 is an **RAR** degrader. Maximal RAR degradation at 30 μM concentration in HT1080 cells.

Purity: 95.02%
Clinical Data: No Development Reported
Size: 1 mg

PROTAC RIPK degrader-2

Cat. No.: HY-111866

PROTAC RIPK degrader-2 is a nonpeptidic **PROTAC** which potently targets serine-threonine kinase **RIPK2** and has highly selective for RIPK2 degradation.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC RIPK degrader-6

Cat. No.: HY-111870

PROTAC RIPK degrader-6 (example 1) is a **PROTAC** targeting **RIP Kinase** degradation wherein the RIP2 kinase inhibitor is linked via a linker to a cereblon binder.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

PROTAC SGK3 degrader-1

(SGK3-PROTAC1) Cat. No.: HY-125878

PROTAC SGK3 degrader-1 (SGK3-PROTAC1), is a potent **SKG3** degrader based on **PROTAC**.



Purity: 99.32%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC Sirt2 Degrader-1

Cat. No.: HY-103636

PROTAC Sirt2 Degrader-1 is a SirReal-based **PROTAC**, acts as a **Sirt2** degrader, composed of a highly potent and isotype-selective **Sirt2** inhibitor, a linker, and a bona fide cereblon ligand for E3 ubiquitin ligase.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

QCA570

Cat. No.: HY-112609

QCA570 is a potent BET degrader based on **PROTAC**, with an IC_{50} of 10 nM for **BRD4 BD1** Protein.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

SD-36

Cat. No.: HY-129602

SD-36 is a potent and efficacious **PROTAC STAT3** degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC_{50}=10 nM).



Purity: 99.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SIAIS178

Cat. No.: HY-128756

SIAIS178 is a potent and selective **BCR-ABL** degrader based on PROTAC technology with an IC_{50} of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase. SIAIS178 has anticancer activity.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

SJF620

Cat. No.: HY-133137

SJF620 is a potent **PROTAC BTK** degrader with a DC_{50} of 7.9 nM. SJF620 contains a Lenalidomide analog for recruiting CRBN.

Purity: 98.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

TD-428

Cat. No.: HY-114407

TD-428 is a highly specific **BRD4** degrader with a DC_{50} of 0.32 nM. TD-428 is a **BET PROTAC**, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

THAL-SNS-032

Cat. No.: HY-123937

THAL-SNS-032 is a selective **CDK9** degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).



Purity: 99.16%
Clinical Data: No Development Reported
Size: 5 mg

UNC6852

Cat. No.: HY-130708

UNC6852 is a selective **polycomb repressive complex 2 (PRC2)** degrader based on PROTAC and contains an EED (embryonic ectoderm development) ligand and a VHL ligand, with an IC_{50} of 247 nM for EED.



Purity: 98.68%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 50 mg

VH032-PEG5-C6-Cl

(HaloPROTAC 2) Cat. No.: HY-112495

VH032-PEG5-C6-Cl (HaloPROTAC 2) is a small molecule HaloPROTAC that incorporates the VH032 based VHL ligand and 5-unit PEG linker. VH032-PEG5-C6-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays.

Purity: 98.10%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

VZ185

Cat. No.: HY-114322

VZ185 is a potent, fast, and selective VHL based dual degrader probe of **BRD9** and **BRD7** with DC_{50}s of 4.5 and 1.8 nM, respectively. VZ185 is cytotoxic in EOL-1 and A-402 cells, with EC_{50}s of 3 nM and 40 nM, respectively.



Purity: >97.0%
Clinical Data: No Development Reported
Size: 1 mg

XZ739

Cat. No.: HY-133557

XZ739, a CRBN-dependent **PROTAC BCL-XL degrader** with a DC_{50} value of 2.5 nM in MOLT-4 cells after 16 h treatment. XZ739 also induces cell death through caspase-mediated **apoptosis**.



Purity: 98.92%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ZXH-3-26

Cat. No.: HY-122826

ZXH-3-26 is a selective PROTAC **BRD4** degrader with a $DC_{50/5h}$. The $DC_{50/5h}$ refers to half-maximal degradation after 5 hours of treatment of ~ 5 nM.



Purity: 98.39%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg